The Food and Drug Administration approvedwho are in remission but still have minimal residual disease (MRD).
This is the first FDA-approved treatment for ALL patients with MRD.
The current approval was based on a single-arm clinical trial of 86 patients in first or second complete remission who had detectable MRD in at least 1 out of 1,000 cells in their bone marrow. Undetectable MRD was achieved by 70 patients after one cycle of blinatumomab treatment. More than half of the patients remained alive and in remission for at least 22.3 months.
Common side effects include bacterial and pathogen-unspecified infections, pyrexia, headache, infusion-related reactions, neutropenia, anemia, febrile neutropenia, and thrombocytopenia. The drug carries a boxed warning about cytokine release syndrome at the start of the first treatment.
Blinatumomab is marketed as Blincyto by Amgen.
FDA News Release: FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse
This Week's Must Reads
Monetary support affects select prescribing, Mitchell AP et al. JAMA Intern Med. 2018 Apr 9. doi: 0.1001/jamainternmed.2018.0776
Best TKI options in ALL, Jabbour E et al. Clin Lymphoma Myeloma Leuk. 2018 18(4):257-65
2 approaches to diagnosing heparin-induced thrombocytopenia, Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103
Blinatumomab eliminates residual B-cell ALL, Gökbuget N et al. Blood. 2018 Apr 5;131(14):1522-31.
Aryl hydrocarbon receptor antagonist boosts cord blood engraftment, Wagner J et al. 2018 Bone Marrow Transplant Tandem Meetings, Abstract 4.